首页 > 最新文献

World Journal of Surgical Oncology最新文献

英文 中文
Multi-omics analysis identifies BUB1B as a cell cycle-related driver of bladder cancer progression. 多组学分析发现BUB1B是膀胱癌进展的细胞周期相关驱动因子。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-12 DOI: 10.1186/s12957-025-04175-5
Huidong Zhou, Shao Peng, Zhixin Ling, Jiaodi Cai, Jinghong Liu, Ying Kong, Hua Zhang, Jun Ouyang, Jianglei Zhang
{"title":"Multi-omics analysis identifies BUB1B as a cell cycle-related driver of bladder cancer progression.","authors":"Huidong Zhou, Shao Peng, Zhixin Ling, Jiaodi Cai, Jinghong Liu, Ying Kong, Hua Zhang, Jun Ouyang, Jianglei Zhang","doi":"10.1186/s12957-025-04175-5","DOIUrl":"10.1186/s12957-025-04175-5","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":"71"},"PeriodicalIF":2.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12888200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The dual oncogenic and protective roles of hashimoto's thyroiditis in papillary thyroid carcinoma: a cohort-based meta-analysis. 桥本甲状腺炎在乳头状甲状腺癌中的双重致癌和保护作用:一项基于队列的荟萃分析。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-10 DOI: 10.1186/s12957-025-04184-4
Xuejiao Ma, Huiyuan Shang, Yanying Zhang, Zhongyuan Xia
{"title":"The dual oncogenic and protective roles of hashimoto's thyroiditis in papillary thyroid carcinoma: a cohort-based meta-analysis.","authors":"Xuejiao Ma, Huiyuan Shang, Yanying Zhang, Zhongyuan Xia","doi":"10.1186/s12957-025-04184-4","DOIUrl":"10.1186/s12957-025-04184-4","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":"70"},"PeriodicalIF":2.5,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12879376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145946497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of novel circulating protein biomarkers for hepatocellular carcinoma superior to alpha-fetoprotein through a stemness index and secretome analysis. 通过干细胞指数和分泌组分析,鉴定出新的肝细胞癌循环蛋白生物标志物优于甲胎蛋白。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-09 DOI: 10.1186/s12957-025-04189-z
Cai Gao, Xuebing Li, Xinwei Liu, Sha Yan, Xiaodan Ran, Jingxian Han
<p><strong>Objective: </strong>This study aimed to identify novel circulating protein biomarkers for hepatocellular carcinoma (HCC) superior to alpha-fetoprotein (AFP) by integrating tumor stemness index and secreted protein screening, and to explore their roles in prognosis, immune microenvironment, and tumor mechanisms.</p><p><strong>Methods: </strong>Stemness-associated differentially expressed genes were identified from TCGA (The Cancer Genome Atlas) and GEO (Gene Expression Omnibus) databases after applying ComBat batch effect correction and quantile normalization to harmonize the datasets. WGCNA (weighted gene co-expression network analysis), secreted protein databases, and plasma sequencing were used to select candidate genes. Functional and immune infiltration analyses were performed, alongside multivariable Cox regression modeling and inverse variance weighted (IVW) MendelianRandomization (MR) for prognostic and causal validation.</p><p><strong>Results: </strong>A total of 19 genes significantly associated with tumor stemness and detectable in circulation were identified. After filtering based on clinicopathological features and survival analysis, 10 key genes were selected. The receiver operating characteristic (ROC) curve analysis revealed that, aside from FCN3 (ficolin 3), the diagnostic sensitivity and specificity of CRHBP (corticotropin-releasing hormone binding protein), CLEC3B (C-type lectin domain family 3 member B), TEK (TEK receptor tyrosine kinase), SOGA1 (SOGA family member 1), IL33 (interleukin 33), CXCL12 (C-X-C motif chemokine ligand 12), NENF (neudesin neurotrophic factor), and ITM2B (integral membrane protein 2B) (AUCs [area under the curves] ranging from 0.67 to 0.99) surpassed those of AFP (AUC = 0.64). Cibersort analysis indicated significant associations of CRHBP, CLEC3B, TEK, IL33, NENF, CXCL12, and AFP with various immune cell infiltrates. The gene set enrichment analysis (GSEA) suggested that CRHBP, CLEC3B, TEK, NENF, and AFP were primarily enriched in cell cycle-related pathways, whereas IL33, CXCL12, SOGA1, and ITM2B were involved in MAPK, GNRH, and NOTCH signaling. A multivariable Cox regression model identified CLEC3B, TEK, and NENF for constructing a prognostic signature, which demonstrated strong predictive performance in the TCGA cohort, as evidenced by the concordance index (C-index), time-dependent ROC analysis (1-/3-/5-year AUCs: 0.74/0.72/0.70), and decision curve analysis. IVW MR analysis further confirmed a causal relationship between cis-expression quantitative trait loci (cis-eQTLs) of the NENF gene and HCC risk (P = 0.024), with no significant pleiotropy or heterogeneity detected. Elevated NENF protein expression, validated by proteomic and immunohistochemical analyses of public databases and a tissue microarray cohort, was significantly associated with HCC progression and reduced overall survival (hazard ratio [HR], 2.456; 95% CI, 1.271-4.960; P = 0.012).</p><p><strong>Conclusion: </strong>This mu
目的:本研究旨在结合肿瘤干性指数和分泌蛋白筛选,寻找优于甲胎蛋白(AFP)的新型肝细胞癌循环蛋白生物标志物,并探讨其在预后、免疫微环境和肿瘤机制中的作用。方法:对TCGA (The Cancer Genome Atlas)和GEO (Gene Expression Omnibus)数据库进行ComBat批效应校正和分位数归一化处理,鉴定出与癌症相关的差异表达基因。WGCNA(加权基因共表达网络分析)、分泌蛋白数据库和血浆测序用于选择候选基因。进行功能和免疫浸润分析,同时进行多变量Cox回归建模和反方差加权孟德尔随机化(MR),以进行预后和因果验证。结果:共鉴定出19个与肿瘤干性显著相关且可在循环中检测到的基因。根据临床病理特征和生存分析进行筛选,筛选出10个关键基因。受试者工作特征(ROC)曲线分析显示,除FCN3 (ficolin 3)外,促肾上腺皮质激素释放激素结合蛋白CRHBP(促肾上腺皮质激素释放激素结合蛋白)、CLEC3B (c型凝集素结构域家族3成员B)、TEK (TEK受体酪氨酸激酶)、SOGA1 (SOGA家族1成员)、IL33(白细胞介素33)、CXCL12 (C-X-C基元趋化因子配体12)、NENF (neudesin神经营养因子)、整体膜蛋白2B (ITM2B)的AUC(曲线下面积)为0.67 ~ 0.99,超过了AFP (AUC = 0.64)。Cibersort分析显示,CRHBP、cle3b、TEK、IL33、NENF、CXCL12和AFP与各种免疫细胞浸润有显著相关性。基因集富集分析(GSEA)表明,CRHBP、cle3b、TEK、NENF和AFP主要富集于细胞周期相关通路中,而IL33、CXCL12、SOGA1和ITM2B则参与MAPK、GNRH和NOTCH信号通路。多变量Cox回归模型确定cle3b、TEK和NENF用于构建预后特征,从一致性指数(C-index)、时间相关ROC分析(1-/3-/5年auc: 0.74/0.72/0.70)和决策曲线分析中可以看出,cle3b、TEK和NENF在TCGA队列中具有较强的预测能力。IVW MR分析进一步证实了NENF基因的顺式表达数量性状位点(cis-eQTLs)与HCC风险之间的因果关系(P = 0.024),未发现明显的多效性或异质性。公共数据库和组织芯片队列的蛋白质组学和免疫组织化学分析证实,NENF蛋白表达升高与HCC进展和总生存率降低显著相关(风险比[HR], 2.456; 95% CI, 1.271-4.960; P = 0.012)。结论:这项多组学研究揭示了一组8种循环蛋白在HCC中的诊断性能优于AFP和独立预后价值,表明NENF是疾病进展和生存的因果生物标志物。
{"title":"Identification of novel circulating protein biomarkers for hepatocellular carcinoma superior to alpha-fetoprotein through a stemness index and secretome analysis.","authors":"Cai Gao, Xuebing Li, Xinwei Liu, Sha Yan, Xiaodan Ran, Jingxian Han","doi":"10.1186/s12957-025-04189-z","DOIUrl":"https://doi.org/10.1186/s12957-025-04189-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This study aimed to identify novel circulating protein biomarkers for hepatocellular carcinoma (HCC) superior to alpha-fetoprotein (AFP) by integrating tumor stemness index and secreted protein screening, and to explore their roles in prognosis, immune microenvironment, and tumor mechanisms.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Stemness-associated differentially expressed genes were identified from TCGA (The Cancer Genome Atlas) and GEO (Gene Expression Omnibus) databases after applying ComBat batch effect correction and quantile normalization to harmonize the datasets. WGCNA (weighted gene co-expression network analysis), secreted protein databases, and plasma sequencing were used to select candidate genes. Functional and immune infiltration analyses were performed, alongside multivariable Cox regression modeling and inverse variance weighted (IVW) MendelianRandomization (MR) for prognostic and causal validation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 19 genes significantly associated with tumor stemness and detectable in circulation were identified. After filtering based on clinicopathological features and survival analysis, 10 key genes were selected. The receiver operating characteristic (ROC) curve analysis revealed that, aside from FCN3 (ficolin 3), the diagnostic sensitivity and specificity of CRHBP (corticotropin-releasing hormone binding protein), CLEC3B (C-type lectin domain family 3 member B), TEK (TEK receptor tyrosine kinase), SOGA1 (SOGA family member 1), IL33 (interleukin 33), CXCL12 (C-X-C motif chemokine ligand 12), NENF (neudesin neurotrophic factor), and ITM2B (integral membrane protein 2B) (AUCs [area under the curves] ranging from 0.67 to 0.99) surpassed those of AFP (AUC = 0.64). Cibersort analysis indicated significant associations of CRHBP, CLEC3B, TEK, IL33, NENF, CXCL12, and AFP with various immune cell infiltrates. The gene set enrichment analysis (GSEA) suggested that CRHBP, CLEC3B, TEK, NENF, and AFP were primarily enriched in cell cycle-related pathways, whereas IL33, CXCL12, SOGA1, and ITM2B were involved in MAPK, GNRH, and NOTCH signaling. A multivariable Cox regression model identified CLEC3B, TEK, and NENF for constructing a prognostic signature, which demonstrated strong predictive performance in the TCGA cohort, as evidenced by the concordance index (C-index), time-dependent ROC analysis (1-/3-/5-year AUCs: 0.74/0.72/0.70), and decision curve analysis. IVW MR analysis further confirmed a causal relationship between cis-expression quantitative trait loci (cis-eQTLs) of the NENF gene and HCC risk (P = 0.024), with no significant pleiotropy or heterogeneity detected. Elevated NENF protein expression, validated by proteomic and immunohistochemical analyses of public databases and a tissue microarray cohort, was significantly associated with HCC progression and reduced overall survival (hazard ratio [HR], 2.456; 95% CI, 1.271-4.960; P = 0.012).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This mu","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone mineral density as a prognostic marker in patients with non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy. 骨矿物质密度作为非小细胞肺癌患者接受新辅助化疗免疫治疗的预后指标。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1186/s12957-025-04186-2
Fengyi Zhou, Peile Li, Ji'an Zou, Weixuan Lei, Wei Han, Yun Gu, Yan Hu, Chao Zeng, Jina Li, Jieming Cao, Quanming Fei, Mengqi Shao, Junqi Yi, Zeyu Cheng, Li Wang, Yazhuo Liu, Wenliang Liu
{"title":"Bone mineral density as a prognostic marker in patients with non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy.","authors":"Fengyi Zhou, Peile Li, Ji'an Zou, Weixuan Lei, Wei Han, Yun Gu, Yan Hu, Chao Zeng, Jina Li, Jieming Cao, Quanming Fei, Mengqi Shao, Junqi Yi, Zeyu Cheng, Li Wang, Yazhuo Liu, Wenliang Liu","doi":"10.1186/s12957-025-04186-2","DOIUrl":"10.1186/s12957-025-04186-2","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":"69"},"PeriodicalIF":2.5,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12879409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a. LncRNA FRMD6-AS2通过靶向miR-1260a抑制膀胱癌的恶性进展。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-07 DOI: 10.1186/s12957-025-04171-9
Peng Dai, Luchang Chen, Zheng Dong, Hailong Wang, Yong Wen
{"title":"LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a.","authors":"Peng Dai, Luchang Chen, Zheng Dong, Hailong Wang, Yong Wen","doi":"10.1186/s12957-025-04171-9","DOIUrl":"10.1186/s12957-025-04171-9","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":"37"},"PeriodicalIF":2.5,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12805699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miR-146b-5p promotes prostate cancer progression by targeting and negatively regulating FOXO3 and its mechanism. miR-146b-5p通过靶向和负调控FOXO3促进前列腺癌进展及其机制。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-06 DOI: 10.1186/s12957-025-04161-x
Baoji Xing, Meini Cen, Yin Yu, Feng Feng, Zhao Wang

Aims: To investigate the expression and potential mechanism of action of miR-146b-5p in prostate cancer (PCa).

Methods: Quantification of miR-146b-5p and FOXO3 expression by RT-qPCR was performed on 140 paired PCa and normal adjacent tissues. Kaplan-Meier curves and Cox regression models were used to analyze the relationship between miR-146b-5p expression and 5-year survival outcomes. In vitro experiments were performed in PC-3 and 22RV1 cells to explore the regulatory relationship between miR-146b-5p and FOXO3.

Results: miR-146b-5p is markedly upregulated in PCa tissues and cell lines, exhibiting a significant correlation with tumor stage, Gleason score, lymph node metastasis, and unfavorable prognosis. miR-146b-5p overexpression promoted PCa cell proliferation, migration, and invasion, while inhibition exerted opposite effects. Bioinformatics prediction and dual-luciferase assay confirmed that miR-146b-5p directly targeted the 3'UTR of FOXO3, negatively regulating its expression. Rescue experiments demonstrated that silencing FOXO3 reversed the inhibitory effects of miR-146b-5p inhibitor on PCa cell malignancy.

Conclusions: miR-146b-5p drives PCa progression through the targeted downregulation of FOXO3, implicating it as a promising prognostic marker and therapeutic target.

目的:探讨miR-146b-5p在前列腺癌(PCa)中的表达及其可能的作用机制。方法:采用RT-qPCR定量检测140对PCa及正常邻近组织中miR-146b-5p和FOXO3的表达。采用Kaplan-Meier曲线和Cox回归模型分析miR-146b-5p表达与5年生存结局的关系。我们在PC-3和22RV1细胞中进行体外实验,探索miR-146b-5p与FOXO3的调控关系。结果:miR-146b-5p在前列腺癌组织和细胞系中显著上调,与肿瘤分期、Gleason评分、淋巴结转移及不良预后有显著相关性。miR-146b-5p过表达促进了PCa细胞的增殖、迁移和侵袭,而抑制则相反。生物信息学预测和双荧光素酶测定证实,miR-146b-5p直接靶向FOXO3的3'UTR,负向调控其表达。挽救实验表明,沉默FOXO3逆转了miR-146b-5p抑制剂对PCa细胞恶性肿瘤的抑制作用。结论:miR-146b-5p通过靶向下调FOXO3来驱动PCa的进展,这意味着它是一个有希望的预后标志物和治疗靶点。
{"title":"miR-146b-5p promotes prostate cancer progression by targeting and negatively regulating FOXO3 and its mechanism.","authors":"Baoji Xing, Meini Cen, Yin Yu, Feng Feng, Zhao Wang","doi":"10.1186/s12957-025-04161-x","DOIUrl":"10.1186/s12957-025-04161-x","url":null,"abstract":"<p><strong>Aims: </strong>To investigate the expression and potential mechanism of action of miR-146b-5p in prostate cancer (PCa).</p><p><strong>Methods: </strong>Quantification of miR-146b-5p and FOXO3 expression by RT-qPCR was performed on 140 paired PCa and normal adjacent tissues. Kaplan-Meier curves and Cox regression models were used to analyze the relationship between miR-146b-5p expression and 5-year survival outcomes. In vitro experiments were performed in PC-3 and 22RV1 cells to explore the regulatory relationship between miR-146b-5p and FOXO3.</p><p><strong>Results: </strong>miR-146b-5p is markedly upregulated in PCa tissues and cell lines, exhibiting a significant correlation with tumor stage, Gleason score, lymph node metastasis, and unfavorable prognosis. miR-146b-5p overexpression promoted PCa cell proliferation, migration, and invasion, while inhibition exerted opposite effects. Bioinformatics prediction and dual-luciferase assay confirmed that miR-146b-5p directly targeted the 3'UTR of FOXO3, negatively regulating its expression. Rescue experiments demonstrated that silencing FOXO3 reversed the inhibitory effects of miR-146b-5p inhibitor on PCa cell malignancy.</p><p><strong>Conclusions: </strong>miR-146b-5p drives PCa progression through the targeted downregulation of FOXO3, implicating it as a promising prognostic marker and therapeutic target.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":"66"},"PeriodicalIF":2.5,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12870093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a prognostic model for thyroid cancer based on mitochondrial metabolism-related genes and immune profiling. 基于线粒体代谢相关基因和免疫谱的甲状腺癌预后模型的建立
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-06 DOI: 10.1186/s12957-025-04169-3
Guorui Wang, Qinchao Feng, Guohua Zhu
{"title":"Development of a prognostic model for thyroid cancer based on mitochondrial metabolism-related genes and immune profiling.","authors":"Guorui Wang, Qinchao Feng, Guohua Zhu","doi":"10.1186/s12957-025-04169-3","DOIUrl":"10.1186/s12957-025-04169-3","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":"67"},"PeriodicalIF":2.5,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12871013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of a novel preoperative computed tomography staging model integrating Immune, Inflammatory, and nutritional biomarkers for prognostic prediction in gastric adenocarcinoma patients undergoing radical resection: a multicenter study. 一种新的术前计算机断层扫描分期模型的开发和验证,该模型整合了免疫、炎症和营养生物标志物,可用于胃癌根治患者的预后预测:一项多中心研究。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-05 DOI: 10.1186/s12957-025-04155-9
Xiaolong Gu, Chaoyang Zhang, Panying Zhang, Guobin Wu, Yang Meng, Chongfei Ma, Yang Li, Zhidong Zhang
{"title":"Development and validation of a novel preoperative computed tomography staging model integrating Immune, Inflammatory, and nutritional biomarkers for prognostic prediction in gastric adenocarcinoma patients undergoing radical resection: a multicenter study.","authors":"Xiaolong Gu, Chaoyang Zhang, Panying Zhang, Guobin Wu, Yang Meng, Chongfei Ma, Yang Li, Zhidong Zhang","doi":"10.1186/s12957-025-04155-9","DOIUrl":"10.1186/s12957-025-04155-9","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":"64"},"PeriodicalIF":2.5,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12870278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Construction and external validation of a prognostic model for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization: a multicenter retrospective cohort study. 肝细胞癌经动脉化疗栓塞患者生存预后模型的构建和外部验证:一项多中心回顾性队列研究
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-05 DOI: 10.1186/s12957-025-04182-6
Fangyi Jin, Hanning Miao, Yuefeng Wang, Yongkang Cui, Kejun Gong, Jian Miao, Yuan Sun

Background: Transarterial chemoembolization (TACE) is a primary treatment for hepatocellular carcinoma (HCC). Despite its benefits, not all patients experience prolonged survival. Hence, this study aimed to develop a prognostic model using data from HCC patients who underwent TACE.

Methods: This study collected patients with hepatocellular carcinoma who received TACE treatment in the Second Hospital of Dalian Medical University from September 2014 to September 2024 and randomly divided them into the training set and the validation set in a 7:3 ratio. Meanwhile, the data of patients who received TACE treatment at Zhongshan Hospital Affiliated to Dalian University from September 2021 to September 2024 were collected for external validation. Univariable and multivariable Cox analyses in the training cohort identified independent risk factors. Based on these factors, two predictive models were established via Cox regression and random survival forest (RSF). The predictive accuracy of models was appraised using the concordance index (C-index) and the area under the receiver operating characteristic curve (AUC). The calibration of models was assessed via calibration curves.

Results: This study collected clinical data from 815 HCC patients receiving TACE. Independent risk factors included tumor size, TNM stage, serum alpha-fetoprotein, TACE therapy count, and post-treatment direct bilirubin, lactate dehydrogenase, and gamma-glutamyl transferase levels. In the RSF model, AUCs for predicting 1-, 3-, and 5-year OS 0.88 (95% CI: 0.81-0.94), 0.80 (95% CI: 0.74-0.86), and 0.75 (95% CI: 0.67-0.81) in the internal validation cohort, and 0.87(95%CI:0.76,0.98), 0.91(95%CI:0.85,0.97) and 0.89(95%CI:0.82,0.96) in the external validation cohort. The Cox regression model yielded AUCs for OS at 1, 3, and 5 years of 0.92 (95% CI: 0.87-0.96), 0.83 (95% CI: 0.76-0.89), and 0.81 (95% CI: 0.74-0.88) in the internal validation cohort, and 0.86(95%CI:0.75,0.97), 0.89(95%CI:0.82,0.96)and 0.90(95%CI:0.81,0.99) in the external validation cohort. Given its superior AUC and C-index, a more interpretable survival nomogram was built using the Cox model.

Conclusions: The prognostic nomogram, constructed based on routine, interpretable clinical features in this study, may help estimate the risk of death in TACE-treated HCC patients. This tool may provide a crucial reference for decision-making in follow-up treatment and rehabilitation.

Trial registration: Not applicable.

背景:经动脉化疗栓塞(TACE)是肝细胞癌(HCC)的主要治疗方法。尽管它有好处,但并非所有患者都能延长生存期。因此,本研究旨在利用接受TACE治疗的HCC患者的数据建立一种预后模型。方法:本研究收集2014年9月至2024年9月在大连医科大学第二医院接受TACE治疗的肝癌患者,按7:3的比例随机分为训练集和验证集。同时,收集2021年9月至2024年9月在大连大学附属中山医院接受TACE治疗的患者数据进行外部验证。培训队列的单变量和多变量Cox分析确定了独立的危险因素。基于这些因素,通过Cox回归和随机生存森林(RSF)建立了两种预测模型。采用一致性指数(C-index)和受试者工作特征曲线下面积(AUC)评价模型的预测精度。通过校正曲线评估模型的校正。结果:本研究收集了815例接受TACE治疗的HCC患者的临床数据。独立危险因素包括肿瘤大小、TNM分期、血清甲胎蛋白、TACE治疗计数、治疗后直接胆红素、乳酸脱氢酶和γ -谷氨酰转移酶水平。在RSF模型中,预测1年、3年和5年OS的auc在内部验证队列中分别为0.88 (95%CI: 0.81-0.94)、0.80 (95%CI: 0.74-0.86)和0.75 (95%CI: 0.67-0.81),在外部验证队列中分别为0.87(95%CI:0.76,0.98)、0.91(95%CI:0.85,0.97)和0.89(95%CI:0.82,0.96)。Cox回归模型在1、3和5年的OS auc在内部验证队列中为0.92 (95%CI: 0.87-0.96)、0.83 (95%CI: 0.76-0.89)和0.81 (95%CI: 0.74-0.88),在外部验证队列中为0.86(95%CI:0.75,0.97)、0.89(95%CI:0.82,0.96)和0.90(95%CI:0.81,0.99)。鉴于其优越的AUC和c指数,使用Cox模型构建了更具解释性的生存nomogram。结论:在本研究中,基于常规的、可解释的临床特征构建的预后图可能有助于估计tace治疗的HCC患者的死亡风险。该工具可为后续治疗和康复决策提供重要参考。试验注册:不适用。
{"title":"Construction and external validation of a prognostic model for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization: a multicenter retrospective cohort study.","authors":"Fangyi Jin, Hanning Miao, Yuefeng Wang, Yongkang Cui, Kejun Gong, Jian Miao, Yuan Sun","doi":"10.1186/s12957-025-04182-6","DOIUrl":"10.1186/s12957-025-04182-6","url":null,"abstract":"<p><strong>Background: </strong>Transarterial chemoembolization (TACE) is a primary treatment for hepatocellular carcinoma (HCC). Despite its benefits, not all patients experience prolonged survival. Hence, this study aimed to develop a prognostic model using data from HCC patients who underwent TACE.</p><p><strong>Methods: </strong>This study collected patients with hepatocellular carcinoma who received TACE treatment in the Second Hospital of Dalian Medical University from September 2014 to September 2024 and randomly divided them into the training set and the validation set in a 7:3 ratio. Meanwhile, the data of patients who received TACE treatment at Zhongshan Hospital Affiliated to Dalian University from September 2021 to September 2024 were collected for external validation. Univariable and multivariable Cox analyses in the training cohort identified independent risk factors. Based on these factors, two predictive models were established via Cox regression and random survival forest (RSF). The predictive accuracy of models was appraised using the concordance index (C-index) and the area under the receiver operating characteristic curve (AUC). The calibration of models was assessed via calibration curves.</p><p><strong>Results: </strong>This study collected clinical data from 815 HCC patients receiving TACE. Independent risk factors included tumor size, TNM stage, serum alpha-fetoprotein, TACE therapy count, and post-treatment direct bilirubin, lactate dehydrogenase, and gamma-glutamyl transferase levels. In the RSF model, AUCs for predicting 1-, 3-, and 5-year OS 0.88 (95% CI: 0.81-0.94), 0.80 (95% CI: 0.74-0.86), and 0.75 (95% CI: 0.67-0.81) in the internal validation cohort, and 0.87(95%CI:0.76,0.98), 0.91(95%CI:0.85,0.97) and 0.89(95%CI:0.82,0.96) in the external validation cohort. The Cox regression model yielded AUCs for OS at 1, 3, and 5 years of 0.92 (95% CI: 0.87-0.96), 0.83 (95% CI: 0.76-0.89), and 0.81 (95% CI: 0.74-0.88) in the internal validation cohort, and 0.86(95%CI:0.75,0.97), 0.89(95%CI:0.82,0.96)and 0.90(95%CI:0.81,0.99) in the external validation cohort. Given its superior AUC and C-index, a more interpretable survival nomogram was built using the Cox model.</p><p><strong>Conclusions: </strong>The prognostic nomogram, constructed based on routine, interpretable clinical features in this study, may help estimate the risk of death in TACE-treated HCC patients. This tool may provide a crucial reference for decision-making in follow-up treatment and rehabilitation.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":"65"},"PeriodicalIF":2.5,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12870106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical, virological, and immunohistochemical features of laryngeal papilloma with low-risk human papillomavirus infection: insights from a 13-year institutional cohort. 低风险人乳头状瘤病毒感染喉乳头状瘤的临床、病毒学和免疫组织化学特征:来自13年机构队列的见解
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-03 DOI: 10.1186/s12957-025-04130-4
Hitoshi Hirakawa, Taro Ikegami, Norimoto Kise, Asanori Kiyuna, Hidetoshi Kinjyo, Shunsuke Kondo, Waku Nakasone, Hiroyuki Maeda, Shinya Agena, Mikio Suzuki
{"title":"Clinical, virological, and immunohistochemical features of laryngeal papilloma with low-risk human papillomavirus infection: insights from a 13-year institutional cohort.","authors":"Hitoshi Hirakawa, Taro Ikegami, Norimoto Kise, Asanori Kiyuna, Hidetoshi Kinjyo, Shunsuke Kondo, Waku Nakasone, Hiroyuki Maeda, Shinya Agena, Mikio Suzuki","doi":"10.1186/s12957-025-04130-4","DOIUrl":"10.1186/s12957-025-04130-4","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"24 1","pages":"6"},"PeriodicalIF":2.5,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12764078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1